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P-glycoprotein (P-gp), an ATP-binding cassette, is able to transport structurally and chemi-
cally unrelated substrates. Over-expression of P-gp in cancer cells significantly decreases
the intercellular amount of anticancer drugs, and results in multidrug resistance in cancer
cells, a major obstacle in cancer chemotherapy. P-gp is mainly localized on the plasma
membrane and functions as a drug efflux pump; however, P-gp is also localized in many
intracellular compartments, such as endoplasmic reticulum, Golgi, endosomes, and lyso-
somes. P-gp moves between the intracellular compartments and the plasma membrane
in a microtubule-actin dependent manner.This review highlights our current understanding
of (1) the intracellular localization of P-gp; (2) the traffic and cycling pathways among the
cellular compartments as well as between these compartments and the plasma mem-
brane; and (3) the cellular factors regulating P-gp traffic and cycling. This review also
presents a potential implication in overcoming P-gp-mediated multidrug resistance by tar-
geting P-gp traffic and cycling pathways and impairing P-gp localization on the plasma
membrane.
Keywords: P-glycoprotein, intracellular localization, traffic, recycling, cell polarization, multidrug resistance in
cancer
INTRODUCTION
P-glycoprotein (P-gp), a 170 kDa membrane protein, is a member
of sub-family B of the ATP-binding cassette (ABC) transporter
superfamily, and is also called ABCB1. P-gp has two structurally
identical halves. Its N-terminal half contains six transmembrane
domains, followed by a large cytoplasmic domain with an ATP-
binding site. Similarly, the C-terminal half also has six transmem-
brane domains and an ATP-binding site (1, 2). Plasma membrane
located P-gp is able to transport many chemically and structurally
unrelated substrates out of the cells, and acts as an efflux pump (1,
2). P-gp is primarily expressed in the liver, kidney, gastrointestinal
tract, and blood brain barrier. P-gp is located on the canalicular
apical membrane of hepatocytes in the liver; on the brush border
of proximal tubule cells in the kidney; and on the apical membrane
of mucosal cells in the small intestine (3). Given the transporting
function of P-gp, these tissue distributions allow P-gp to excrete
endogenous metabolites, exogenous substrates, and toxins into the
urine, bile, and feces. Thus, P-gp can protect the organism as well
as eliminate cellular wastes (3, 4). Furthermore, another essential
localization of P-gp is on the luminal surface of capillary endothe-
lial cells of the blood brain barrier which prevents cytotoxins from
penetrating the endothelium and protects brain (5).
Although animal well-being, normal physiological function,
and life span were not affected after P-gp was knocked out in
mice, higher drug sensitivity and increased drug side effect/toxicity
occurred (6). While knocking out P-gp appears to be less prob-
lematic, over-expression of P-gp causes major concerns in clinical
oncology. The most notable consequence of over-expression of P-
gp in clinic is to cause multiple drug resistance (MDR) in cancer
chemotherapy (2). Given P-gp has a structurally broad range of
substrates, the occurrence of MDR during chemotherapy is one of
the big challenges for successful cancer treatment in clinic. MDR
can be either intrinsic, occurring in cancers that have not been
exposed to chemotherapy before but derived from tissue naturally
expressing P-gp (e.g., liver, kidney, intestinal cancers), or required
MDR, which develops after cancers are treated with chemotherapy
(7). Nearly half of human cancers express P-gp at levels sufficient
to develop MDR. The likelihood of failure in chemotherapy is
increased when P-gp expression is upregulated during therapy (8).
INTRACELLULAR LOCALIZATION OF P-gp
P-glycoprotein is primarily localized on the plasma membrane
for its efflux function, however, it is also localized intracellularly
(9, 10). Using immunofluorescence and over-expression of P-gp-
GFP fusion protein approaches, co-localization results revealed
that P-gp is localized in many cellular organelles, including endo-
plasmic reticulum (ER) (9), Golgi (9), early endosome (11–13),
recycling endosome (12), later endosome, lysosome (9, 11), and
proteasome (14) (Figure 1). These intracellular localizations link
to synthesis (ER), modification (Golgi), traffic/recycling (Golgi
and endosomes), and degradation (lysosome and proteasome)
sites for P-gp. Although one study suggests P-gp is also located
in mitochondria in doxorubicin-resistant K562 human leukemia
cells (15), others reveal that P-gp is not presented in mitochon-
dria either in MCF-7 (ADR) human breast cancer and KB-V1
human cervix carcinoma drug resistant cell lines (16) or in pri-
mary rat hepatocytes (17). Furthermore, transient transfection of
P-gp-GFP in cancer cells reveals that the ER and Golgi localization
of P-gp appears to be transient, suggesting that P-gp can rapidly
traffic to the endosomal compartment and the plasma membrane
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FIGURE 1 | Intracellular localization, traffic, and recycling of
P-glycoprotein. P-gp is shown as “green dot .” Different Rab GTPases
that are involved in P-gp traffic and recycling are indicated as “black diamond
.” Arrows represent the traffic and recycling path among the intracellular
organelles and between the cellular organelles and the plasma membrane.
localization after it is synthesized in ER and modified in Golgi.
This rapid transport to the membrane localization explains why
less ER or Golgi localization can be observed in the stable cell line
which is overexpressed with P-gp-GFP. It is possible that activity
of P-gp synthesis remains at a relatively low level due to the very
long half-life of P-gp (14–17 h) in the stable cell line (18). Sim-
ilarly, the degradation localization (lysosome) also appears to be
less common within the cells compared to the endosomal local-
ization which is involved in constantly trafficking/recycling P-gp
between the cellular pool and the plasma membrane (11).
INTRACELLULAR TRAFFIC AND RECYCLING OF P-gp
After synthesis in ER, P-gp first needs to be correctly folded before
exit from ER and entry to Golgi for modification. Currently, very
little information is available about the exact regulatory process
for P-gp folding in ER. Glycoprotein glucosyl transferase (UGGT)
is able to sense the folding states of glycoproteins, resulting in
mis-folded glycoprotein rebinding calnexin (a chaperon for pro-
tein folding) and going through re-folding cycles or being rapidly
degraded via endoplasmic-reticulum-associated protein degrada-
tion (ERAD) (19). Thus, UGGT may play a potential role in
recognizing the folding of P-gp. Moreover, a study suggests that
SPTLC1 (Serine palmitoyltransferase enzyme 1) is able to interact
with ABCA1 and cause ER retention of ABCA1, revealing the role
of SPTLC1 in ER exit of ABC transporters (20). Furthermore, the
formation of disulfide bonds is a critical step in the maturation of
the majority of the proteins inside ER (21). Studies showed that
two other ABC transporters, ABCB6 and ABCC8, form the disul-
fide bonds between highly conserved cysteine, which is important
for these ABC transporters to exit ER and traffic to the plasma
membrane (22). We still lack direct evidence of how P-gp export at
the ER – the first step of its trafficking along the biosynthetic secre-
tory pathway. In mammalian cells, the ER export occurs via Coat
Protein II (COPII)-coated vesicles. COPII vesicles bud from the
ER and are able to fuse to ER-Golgi intermediated compartment
(23). Studies reveal that COPII plays an essential role in exporting
ABCB1 and ABCC7 (cystic fibrosis transmembrane conductance
regulator, CFTR) from ER to Golgi (24, 25), suggesting COPII
may regulate ER export of P-gp as well. Golgi is involved in the
biosynthesis of glycan chains of glycoproteins, the 150 kDa P-gp is
transported to the Golgi and glycosylated as the 170 kDa mature
protein (26) (Figure 1).
After its modification in Golgi, the 170 kDa mature P-gp traf-
fics to the plasma membrane. Membrane proteins can traffic to
the plasma membrane via either the constitutive pathway which
involves membrane protein-containing vesicles moving directly to
the plasma membrane (27, 28) or the endosomal pathway in which
protein-containing vesicles are first transported to endosomal
compartments to establish the intracellular pool, and then traf-
fic to the plasma membrane (29). In both cases, the cytoskeleton is
needed for the traffic of these membrane protein vesicles (30). The
trans-Golgi network (TGN) is a major sorting site for proteins traf-
ficking to the plasma membrane and endosomal pathway. A study
suggests that membrane proteins use N -glycan chains as sorting
determinants (31); whether this also applies to P-gp needs to be
investigated. However, some studies show that N-glycosylation at
amino acid residue asparagine 596 at third extracellular loop is
not necessary for ABCG2 traffic (32), and the immature core-
glycosylated CFTR (ABCC7) can be transported to the plasma
membrane and is functional (33).
In the non-polarized cancer cells, P-gp was reported localized in
EEA1 and Rab5 positive early endosome which serves as an intra-
cellular reservoir prior to P-gp moving to the plasma membrane
(11), suggesting that P-gp can traffic to the plasma membrane
via the indirect endosomal pathway. Furthermore, immunoflu-
orescence study showed that P-gp is also localized in lysosome
after transient expression of human P-gp-GFP in HeLa cells or in
the human breast cancer MCF-7 cells, which are stably expressed
with P-gp-GFP, suggesting P-gp can be moved to the lysosomal
degradation compartment, presumably through the early and late
endosome (12). However, an immunofluorescence study reveals
that P-gp is not localized in Rab11 positive recycling endosomes
in human breast cancer MCF-7 cells, which stably express P-gp-
GFP (11). In the polarized WIFB9 cells as well as hepatocytes,
apical ABC transporters (e.g., P-gp, ABCB11) move to the apical
membrane via Rab11a recycling endosomes and recycle between
the apical membrane and the Rab11a positive intracellular endo-
somal pool (29, 34) (Figure 1). These studies suggest that P-gp
traffics and recycles via different endosomal pathways (early endo-
some vs. recycling endosome) in non-polarized cells (e.g., cancer
cells) and polarized cells.
REGULATION OF P-gp TRAFFIC AND RECYCLING – ROLE OF
Rab GTPases
Rab GTPases, the largest branch of small GTPase, are known to
regulate vesicular transport in exocytosis, endocytosis, and recy-
cling by controlling many steps in membrane trafficking such as
vesicle formation, movement, uncoating, docking, and fusion (35).
So far more than 70 Rab GTPases have been identified in humans
(35). Each Rab protein is believed to be specifically associated
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with a particular organelle or pathway (35). Currently, few stud-
ies revealed the role of Rab proteins in P-gp trafficking, thus, the
more general involvement of Rab proteins in ABC transporters
trafficking and recycling will be discussed.
Rab1, 2, and 6 are localized in ER and Golgi and regulate
vesicle transport along the ER-Golgi biosynthetic pathway. Rab1,
2 regulate vesicle movement from ER to Golgi (35, 36), while
Rab6 is involved in Golgi to the cell surface for exocytosis of
newly synthesized proteins and lipids (37). Study showed that
P-gp was predominantly intracellular, largely in Rab6-containing
Golgi vesicles and Golgi cisternae (7), suggesting Rab6 may reg-
ulate P-gp traffic directly from Golgi to the plasma membrane
(Figure 1).
Along the endosomal trafficking pathway, Rab11 and Rab13
are involved in membrane protein traffic from Golgi to the recy-
cling endosome (38–40). Rab11a was shown to regulate P-gp and
ABCB11 traffic to the apical membrane in polarized WIFB9 cells
(29, 34) (Figure 1). Furthermore, studies showed that Rab11a was
also needed for both WT-CFTR and∆F508-CFTR to undergo traf-
ficking to the apical recycling compartment in polarized human
airway epithelia cells (41) as well as polarized intestinal epithe-
lial cells (42). These studies reveal that, in polarized cells, P-gp
traffics to the apical membrane via the Rab11a positive recy-
cling endosome. However, in non-polarized MCF-7 cells, stable
expressed P-gp-EGFP did not co-localize with Rab11 positive
recycling endosome (11), suggesting P-gp does not traffic to the
cell surface via the Rab11a positive recycling endosome. Evidence
indicates that membrane trafficking of CFTR is cell type-specific
and it differs in polarized human airway epithelial cells such as
CFBE41o- cells and in non-polarized fibroblasts such as BHK-
21 cells (41). Thus, Rab11a may have a differential role in P-gp
trafficking in non-polarized and polarized cells. Other Rab pro-
teins, such as Rab17, Rab25, Rab35, and Rab40 are also localized
in recycling endosome (36, 43). Rab35 is shown to play impor-
tant role in insulin-stimulated GLUT4 (Glucose transporter type
4) translocation in adipocytes (44). Further studies are needed to
investigate the role of Rab11 as well as other Rab proteins (e.g.,
Rab17, Rab25, Rab35, and Rab40) in P-gp traffic in both polarized
and non-polarized cells.
Early endosomal pathway is shown to be involved in P-gp traf-
ficking and recycling. Among many of the early endosomal Rab
proteins, Rab4 and Rab5 are known to regulate P-gp trafficking
and recycling in many cancer cells (12, 13, 45). Over-expression
of dominant-negative Rab5 mutant (S34N-Rab5) results in large
intracellular accumulation of P-gp-EGFP in non-polarized Hela
cells, and similar cellular accumulation of wild type P-gp in
multidrug resistant MCF-7/Adr cells, revealing that Rab5 regu-
lates P-gp exocytosis from the endosome compartment (such as
early endosome) to the plasma membrane in non-polarized cells
(12). In contrast, another study in colon cancer cells LS174T,
demonstrated that over-expression of wild-type Rab5 resulted
in recycling P-gp from the plasma membrane into intracellular
compartments, suggesting that Rab5 regulates P-gp endocytosis
instead of exocytosis (13), however, this study did not investi-
gate the polarization status of the cell culture of LS174T, which
is shown to be polarized in normal culture condition (46). Thus,
the differential role of Rab5 in P-gp trafficking and recycling in
these cancer cells may be related to the difference in polarization
(Figure 1).
Rab4 is also localized in early endosome and shown to regulate
P-gp exocytosis in drug resistant leukemia cells, K562ADR (45).
Cell surface expression of P-gp decreased after over-expression
of GFP-Rab4 or constitutively active Rab4Q72L mutant, but not
dominant-negative Rab4S27N mutant or Rab14 in the K562ADR
cells, suggesting that Rab4 regulates P-gp trafficking to the plasma
membrane from endosomal compartments (45). However, in
HeLa cells, the intracellular localization of P-gp-EGFP was not
affected when there was over-expression of either wild-type Rab4
or dominant-negative mutant N121I-Rab4 respectively (12), indi-
cating Rab4 does not effect P-gp trafficking. The different cell
lines used in these studies may be the reason for obtaining dif-
ferent results. Given many other Rab proteins, such as Rab10,
14, 15, 17, 22, and 23 are localized on early endosome (43),
it is likely these Rab proteins can also regulate the trafficking
and recycling of P-gp between the early endosomal compart-
ment and the plasma membrane in a cell and tissue type-specific
manner.
Transmembrane proteins can be transported from late endo-
some to lysosome which is responsible for degradation of the
membrane proteins (47). P-gp is localized in Lamp-2 positive
lysosome, revealing its lysosomal dependent degradation path-
way (11). Rab7 is localized on late endosome and lysosome, and
is essential for later endocytic membrane trafficking from late
endosome to lysosome (48, 49), while Rab9 is localized on later
endosome and responsible for transit from later endosome to the
TGN (50). Although very little is known about the role of Rab7 and
9 on later endocytic membrane trafficking of P-gp, Rab7 and 9 are
shown to regulate other ABC transporter trafficking (e.g., CFTR).
Using over-expression of wild type and mutant Rab GTPases, a
study revealed that CFTR could enter Rab7-dependent late endo-
somal traffic or Rab9-mediated translocation to the TGN (51),
suggesting the role of both Rab7 and 9 in later endocytic traffick-
ing of CFTR. However, the potential roles of Rab7 and 9 on P-gp
trafficking need to be investigated (Figure 1).
CLINICAL IMPLICATIONS
P-glycoprotein plays an important role in drug excretion and is one
of the main causes for MDR in cancer chemotherapy. Different
generations of P-gp inhibitors are developed and enter into pre-
clinical and clinical studies. The first generation of P-gp inhibitors,
such as verapamil and cyclosporin A, are active substrates of P-gp.
Both verapamil and cyclosporin A cause side effects in patients
due to high dose of the drugs are need for their inhibition of P-gp
(52, 53). The second generation of P-gp inhibitors include valspo-
dar (PSC 833), dexverapamil, and dofequidar fumarate. However,
these second generation inhibitors also inhibit drug metabolism
enzymes and other ABC transporters, which results in impaired
drug metabolism and elimination (54–56). The third generation
of P-gp inhibitors, which are currently undergoing clinical trials,
include zosuquidar (LY335979),elacridar (GF120918),CBT-1,and
XR9576 (57–60). However, some of the trials are unsuccessful in
improving therapeutic efficacy (61). For example, trial was stopped
in patient with non-small-cell lung cancer due to chemotherapy-
related toxicity after administration of XR9576 (60). Thus, there
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is an urgent need to develop innovative strategies to overcome
P-gp-mediated MDR in cancer chemotherapy.
Given P-gp needs to be transported to the plasma membrane so
as to efflux the anticancer drugs out of cells,blocking the trafficking
of P-gp to its final destination – the plasma membrane location –
can be an innovative approach to overcome MDR and improve
therapy. There are multiple potential targets along the P-gp traf-
fic pathway. Study revealed that inhibition of P-gp maturation
resulted in accumulation of P-gp in Golgi, and this immature
P-gp in Golgi was inactive and presumably led to degradation.
Consequently there was an increased cellular accumulation of
P-gp substrate (62). Experiments also reveal that blocking P-gp
traffic to the plasma membrane by interrupting the cytoskele-
ton highway or modulating Rab activation can cause increased
intracellular accumulation of P-gp, resulting in more intracellular
retention of anticancer drug (9, 11, 12). Although the intracel-
lular P-gp that is trapped on the way to the plasma membrane
remains active, it is likely that intracellular P-gp do not contribute
to drug resistance (63). It is essential to identify the regulatory
effectors, such as specific Rab GTPases or Rab binding proteins
for P-gp traffic and recycling, and to screen potential candidates
for targeting these effectors. Therefore, more studies are needed
to understand the molecular and cellular mechanisms of P-gp
intracellular traffic/cycling and its regulatory factors.
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